Muhammad Shaikh
Psychiatry · Bridgeville, PANPI 1497855340
Payments from drug & device makers
Across 269 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$435
- Takeda Pharmaceuticals U.S.A., Inc.$419
- Sunovion Pharmaceuticals Inc.$364
- Ironshore Pharmaceuticals Inc.$284
- Corium, LLC$191
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,66697%
- Education$1303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,483 |
| Alkermes, Inc. | 22 | $435 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $419 |
| Sunovion Pharmaceuticals Inc. | 26 | $364 |
| Ironshore Pharmaceuticals Inc. | 14 | $284 |
| Corium, LLC | 10 | $191 |
| Neos Therapeutics, LP | 9 | $187 |
| Teva Pharmaceuticals USA, Inc. | 4 | $172 |
| Indivior Inc. | 11 | $168 |
| Neurocrine Biosciences, Inc. | 8 | $158 |
| Almatica Pharma LLC | 9 | $149 |
| Otsuka America Pharmaceutical, Inc. | 8 | $146 |
| Supernus Pharmaceuticals, Inc. | 8 | $120 |
| Lundbeck LLC | 6 | $111 |
| Johnson & Johnson | 5 | $103 |
| Tris Pharma Inc | 3 | $49 |
| Biodelivery Sciences International, Inc. | 4 | $47 |
| Shire North American Group Inc | 3 | $44 |
| Vertical Pharmaceuticals, LLC | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Neuronetics, Inc. | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$4,796 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 15 | $3,521 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $1,153 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $745 |
| Hydroxyzine Pamoate | 55 | $738 |
| Trazodone Hcl | 49 | $622 |
| Prazosin Hcl | 28 | $453 |
| Quetiapine Fumarate | 29 | $444 |
| Topiramate | 14 | $420 |
| Duloxetine Hcl | 24 | $284 |
| Buspirone Hcl | 29 | $240 |
| Amitriptyline Hcl | 15 | $222 |
| Sertraline Hcl | 30 | $206 |
| Clonazepam | 37 | $193 |
| Lamotrigine | 19 | $186 |
| Lithium Carbonate ErLithium Carbonate | 11 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $149 | $20630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Bridgeville
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.